Navigation Links
American Urological Association (AUA) Clinical Guidelines Recognizes Cryotherapy as Treatment Option for Prostate Cancer Patients
Date:5/21/2008

The New Best Practice Statements Were Presented at the AUA Annual Meeting Being Held in Orlando, Florida

YOKNEAM, Israel and PLYMOUTH MEETING, Pennsylvania, May 21 /PRNewswire/ -- Galil Medical, a global leader in cryotherapy, announced today that the American Urological Association has introduced clinical guidelines with best practice statements for prostate cryotherapy. The guidelines state that cryoablation is a treatment option for men with clinically confined prostate cancer of any grade and that salvage cryoablation is a treatment option in men who have failed radiation therapy.

Prostate cryotherapy uses extreme cold to freeze and destroy prostate cancer cells. This minimally invasive procedure is routinely and successfully performed on prostate cancer patients with varying disease stages as well as those who have failed radiation treatment. Prostate cancer is the most common cancer, other than skin cancers, in American men. The American Cancer Society estimates that during 2008 about 186,320 new cases of prostate cancer will be diagnosed in the United States.

The American Urological Association (AUA), the premier professional association for the advancement of urologic patient care, routinely adopts clinical guidelines and best practice statements, releasing updates as technology improves. Dr. Richard Babaian, Professor and Senior Medical Director at the MD Anderson Physician Network, presented the new guidelines for cryotherapy for the treatment of localized prostate cancer at the plenary session of the AUA annual meeting.

Martin J. Emerson, Galil Medical President and CEO comments, "We are pleased that the AUA, in its preeminent role in assessing new treatment options for urologists and their patients, now recognizes cryotherapy as a mainstream treatment option for patients diagnosed with localized prostate cancer."

Urologists can learn first-hand about cryotherapy at the Cryosurgical Ablation of the Prostate course being presented during the AUA annual meeting on Thursday, May 22, 2008 from 6-8 a.m.

A recently published retrospective study of primary prostate cryotherapy by Dr. Jeffrey Cohen reported 10-year follow up data with biochemical control comparable to external beam radiotherapy or prostate brachytherapy. The literature has also shown that advances over the last 10 years in cryoablation techniques have dramatically improved the morbidity profile.

New guidelines for the treatment of localized prostate cancer were released by the AUA in 2007 and emphasized communication with the patient regarding risk, treatment options, and potential outcomes. At that time, it was recognized that cryotherapy for the treatment of localized prostate cancer should be the topic of an AUA best practice policy.

About Galil Medical

Galil Medical develops, manufactures and markets innovative products utilizing a proprietary cryotherapy platform that incorporates powerful freezing technology and revolutionary 17-gauge cryoablation needle design. Galil Medical systems enable minimally invasive, targeted ablation of benign and cancerous tumors while ensuring rapid recovery and enhanced quality of life for patients. The Presice(TM) Cryoablation System features multi-point thermal sensors (MTS) and advanced IceVue(TM) planning software for excellent procedure control in treating prostate and renal cancer. The SeedNet(TM) system provides physicians with an easy-to-use cryoablation solution to precisely ablate tumors while protecting adjacent structures.

Galil Medical is a global medical device company with offices in Yokneam, Israel; Plymouth Meeting, Pennsylvania; and London, Shareholders include Thomas, McNerney & Partners, The Vertical Group, Investor Growth Capital, Elron Electronic Industries Ltd. (NASDAQ:ELRN) and RDC Rafael Development Corporation, Ltd. For more information, please visit http://www.galilmedical.com

NOTE:

"Galil Medical has received approval from Elron Electronic Industries Ltd. (NASDAQ: ELRN) to have the announcement associated with its ticker. Please associate this announcement also to the ELRN ticker."

Contact:

Pam Schwartz

Communications Manager

Galil Medical

T: +972-4-909-3273

M: +972-52-625-4443

F: +972-4-959-1077

pam.schwartz@galilmedical.com


'/>"/>
SOURCE Galil Medical Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Coalition for Pulmonary Fibrosis and American Thoracic Society Continue Research Partnership Through 2010
2. Elseviers Engineering Village Search Platform Combines the American Geological Institutes Georef Database With Google Maps
3. American Oriental Bioengineering Forms Science and Technology Advisory Committee
4. Bayer and Onyx Announce Nexavar Data Presentations at 44th American Society of Clinical Oncology Annual Meeting
5. Forest Laboratories, Inc. and Laboratorios Almirall, S.A. to Host Webcast to Discuss Aclidinium Bromide Data Presentations at the American Thoracic Society Annual Congress
6. Depth of MedImmunes Respiratory Disease Research Program Highlighted at Annual Meeting of the American Thoracic Society
7. American Oriental Bioengineering Comments on Earthquake
8. Moffitt Cancer Center Joins National Campaign To Implore Americans To Donate $1 To Accelerate Cancer Research
9. American Oriental Bioengineering Reports First Quarter 2008 Financial Results
10. LifeQuest World Launches Immune System Boosting Supplement to the North American Market
11. American Psychiatric Foundation Announces Recipients of 2008 Awards for Advancing Minority Mental Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... Lajollacooks4u is proud to announce it has ... has hosted corporate cooking challenges for companies around the world, such as Illumina, HP and ... of the reason for its increasing popularity is due to its new team building format, ...
(Date:3/23/2017)... March 23, 2017  GlobeImmune, Inc. today announced it ... sale of 12,835,490 shares of its common stock to ... companies. In connection with the sale of its common stock, ... and issue to GlobeImmune 200,000 shares, an estimated $2.0 ... "We are pleased to enter into this strategic ...
(Date:3/23/2017)... NetworkNewsWire Editorial Coverage  ... Cancer remains one of the world,s ... systems, in terms of costs and resources. However, as the ... of innovative and efficient therapies that demonstrate higher chances of ... cancer treatments, a growing number of patients receiving immuno-oncology therapies ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ... solutions, today announced the hire of Dr. Sigmund “Sig” Floyd as Vice President ... strategic partnerships and joint development activities. , “Dr. Floyd’s career has spanned 30 ...
Breaking Biology Technology:
(Date:2/27/2017)... Feb. 27, 2017   Strategic Cyber Ventures , ... has led a $3.5 million investment in  Polarity , ... Cyber Ventures is DC based and is led by ... Thomas . Ron Gula , also a longtime ... participated in this series A round of funding. This ...
(Date:2/24/2017)... Spain , Feb. 24, 2017  EyeLock LLC, a ... demonstrate its elite iris biometric solution on the ... X16 LTE at Mobile World Congress 2017 ... Qualcomm,s Booth in Hall 3, Stand 3E10. ... the Qualcomm Haven™ security platform—a combination of ...
(Date:2/21/2017)... PORTLAND, Ore. , Feb. 22, 2017  IBM ... Companies (Avamere Health Services, Infinity Rehab, Signature Hospice, Home ... that will apply the power of IBM cognitive computing ... health centers. By analyzing data streaming from sensors in ... physical and environmental conditions, and obtain deeper learnings into ...
Breaking Biology News(10 mins):